- Home
- RARE vs ARW Comparison
RARE vs ARW Comparison
Compare RARE & ARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ARW
- Stock Information
- Founded
- RARE 2010
- ARW 1935
- Country
- RARE United States
- ARW United States
- Employees
- RARE N/A
- ARW N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ARW Electronic Components
- Sector
- RARE Health Care
- ARW Technology
- Exchange
- RARE Nasdaq
- ARW Nasdaq
- Market Cap
- RARE 5.2B
- ARW 5.9B
- IPO Year
- RARE 2014
- ARW N/A
- Fundamental
- Price
- RARE $40.89
- ARW $119.25
- Analyst Decision
- RARE Strong Buy
- ARW Hold
- Analyst Count
- RARE 15
- ARW 4
- Target Price
- RARE $92.00
- ARW $121.75
- AVG Volume (30 Days)
- RARE 1.0M
- ARW 437.4K
- Earning Date
- RARE 02-13-2025
- ARW 02-06-2025
- Dividend Yield
- RARE N/A
- ARW N/A
- EPS Growth
- RARE N/A
- ARW N/A
- EPS
- RARE N/A
- ARW 8.98
- Revenue
- RARE $522,745,000.00
- ARW $28,489,604,000.00
- Revenue This Year
- RARE $26.70
- ARW N/A
- Revenue Next Year
- RARE $19.02
- ARW $2.09
- P/E Ratio
- RARE N/A
- ARW $13.27
- Revenue Growth
- RARE 27.44
- ARW N/A
- 52 Week Low
- RARE $37.02
- ARW $108.51
- 52 Week High
- RARE $60.37
- ARW $137.80
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- ARW 60.47
- Support Level
- RARE $39.99
- ARW $110.61
- Resistance Level
- RARE $44.52
- ARW $113.05
- Average True Range (ATR)
- RARE 2.18
- ARW 2.43
- MACD
- RARE -0.03
- ARW 0.89
- Stochastic Oscillator
- RARE 17.75
- ARW 85.19
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.